Blocking cholesterol esterification improves treatment outcomes, particularly for liver cancers with p53 deletions/mutations that originate in a background of non-alcoholic fatty liver disease. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatotic liver disease.